Anatara Lifesciences (ASX:ANR) received a patent for its Gastrointestinal ReProgramming (GaRP) product, under the invention title "Gastrointestinal Health Composition," according to a Tuesday filing with the Australian bourse.
The intellectual property protection, granted by the Australian Patent Office, has a 20-year term from Oct. 9, 2020, to Oct. 9, 2040, the filing said.
The GaRP product is a complementary medicine designed to tackle the root causes of chronic gastrointestinal conditions like irritable bowel syndrome and inflammatory bowel disease, per the filing.
Its shares fell 8% in afternoon trade Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。